纤溶酶原激活物抑制剂-1 与 2 型糖尿病患者的肾功能障碍相关，与 BMI 和血清脂质水平无关。
Plasminogen activator inhibitor-1 is associated with renal dysfunction independent of BMI and serum lipid levels in patients with type 2 diabetes.
机构信息
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama-City University, Yokohama, Japan.
出版信息
Diabetes Res Clin Pract. 2012 Jul;97(1):e9-12. doi: 10.1016/j.diabres.2012.03.017. Epub 2012 Apr 10.
Abstract
We investigated a possible association between serum plasminogen activator inhibitor-1 (PAI-1) levels and renal dysfunction in 124 type 2 diabetes patients. Multiple linear regression analyses indicated that the PAI-1 levels were significantly inversely correlated with estimated glomerular filtration rate (eGFR) independent of albuminuria, BMI, LDL-C, and triglyceride.
摘要
我们调查了 124 例 2 型糖尿病患者血清纤溶酶原激活物抑制剂-1（PAI-1）水平与肾功能不全之间的可能关联。多元线性回归分析表明，PAI-1 水平与估计肾小球滤过率（eGFR）显著负相关，与白蛋白尿、BMI、LDL-C 和甘油三酯无关。
Zotero 插件